Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy

and the Korean Multiple Myeloma Working Party

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The revised International Staging System (R-ISS) has recently been developed to improve the risk stratification of multiple myeloma (MM) patients over the ISS. We assessed the R-ISS in MM patients who were treated with novel agents as a primary therapy and evaluated its discriminative power and ability to reclassify patients from the ISS. A total of 514 newly diagnosed MM patients treated with novel agents including thalidomide, bortezomib, and lenalidomide as a primary therapy were included in this retrospective analysis. With a median follow-up duration of 42.3 months (range, 40.5–44.1), the median overall survival (OS) was 61.0 months. There was a significant difference in median OS (not reached, 60.9, and 50.1 months for stages 1, 2, and 3, respectively, P < 0.001) among the three stages of R-ISS. The C-statistic was significantly greater for R-ISS than for ISS (0.769 vs. 0.696, P < 0.001). The event NRI was −0.08 (95% confidence interval [CI], −0.18–0.01) and the non-event NRI was 0.05 (95% CI, −0.03–0.10), resulting in a total NRI of −0.03 (95% CI, −0.14–0.08, P = 0.602). The R-ISS performs well and has significantly better discriminative power than the ISS in MM patients treated with novel agents as a primary therapy. However, it does not better reclassify patients from the ISS, suggesting that there is still room to improve the staging system. Moreover, new statistical measures for assessing and quantifying the risk prediction of new prognostic models are necessary in future studies.

Original languageEnglish
Pages (from-to)1280-1286
Number of pages7
JournalAmerican Journal of Hematology
Volume92
Issue number12
DOIs
Publication statusPublished - 2017 Dec 1

Fingerprint

Multiple Myeloma
Confidence Intervals
Therapeutics
Thalidomide
Survival

ASJC Scopus subject areas

  • Hematology

Cite this

Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy. / and the Korean Multiple Myeloma Working Party.

In: American Journal of Hematology, Vol. 92, No. 12, 01.12.2017, p. 1280-1286.

Research output: Contribution to journalArticle

@article{a145573294dc4ef8b485c263beb355d8,
title = "Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy",
abstract = "The revised International Staging System (R-ISS) has recently been developed to improve the risk stratification of multiple myeloma (MM) patients over the ISS. We assessed the R-ISS in MM patients who were treated with novel agents as a primary therapy and evaluated its discriminative power and ability to reclassify patients from the ISS. A total of 514 newly diagnosed MM patients treated with novel agents including thalidomide, bortezomib, and lenalidomide as a primary therapy were included in this retrospective analysis. With a median follow-up duration of 42.3 months (range, 40.5–44.1), the median overall survival (OS) was 61.0 months. There was a significant difference in median OS (not reached, 60.9, and 50.1 months for stages 1, 2, and 3, respectively, P < 0.001) among the three stages of R-ISS. The C-statistic was significantly greater for R-ISS than for ISS (0.769 vs. 0.696, P < 0.001). The event NRI was −0.08 (95{\%} confidence interval [CI], −0.18–0.01) and the non-event NRI was 0.05 (95{\%} CI, −0.03–0.10), resulting in a total NRI of −0.03 (95{\%} CI, −0.14–0.08, P = 0.602). The R-ISS performs well and has significantly better discriminative power than the ISS in MM patients treated with novel agents as a primary therapy. However, it does not better reclassify patients from the ISS, suggesting that there is still room to improve the staging system. Moreover, new statistical measures for assessing and quantifying the risk prediction of new prognostic models are necessary in future studies.",
author = "{and the Korean Multiple Myeloma Working Party} and Hyungwoo Cho and Yoon, {Dok Hyun} and Lee, {Jung Bok} and Kim, {Sung Yong} and Moon, {Joon Ho} and Do, {Young Rok} and Lee, {Jae Hoon} and Yong Park and Lee, {Ho Sup} and Eom, {Hyeon Seok} and Shin, {Ho Jin} and Min, {Chang Ki} and Kim, {Jin Seok} and Jo, {Jae Cheol} and Kang, {Hye Jin} and Mun, {Yeung Chul} and Lee, {Won Sik} and Lee, {Je Jung} and Cheolwon Suh and Kihyun Kim",
year = "2017",
month = "12",
day = "1",
doi = "10.1002/ajh.24891",
language = "English",
volume = "92",
pages = "1280--1286",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "12",

}

TY - JOUR

T1 - Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy

AU - and the Korean Multiple Myeloma Working Party

AU - Cho, Hyungwoo

AU - Yoon, Dok Hyun

AU - Lee, Jung Bok

AU - Kim, Sung Yong

AU - Moon, Joon Ho

AU - Do, Young Rok

AU - Lee, Jae Hoon

AU - Park, Yong

AU - Lee, Ho Sup

AU - Eom, Hyeon Seok

AU - Shin, Ho Jin

AU - Min, Chang Ki

AU - Kim, Jin Seok

AU - Jo, Jae Cheol

AU - Kang, Hye Jin

AU - Mun, Yeung Chul

AU - Lee, Won Sik

AU - Lee, Je Jung

AU - Suh, Cheolwon

AU - Kim, Kihyun

PY - 2017/12/1

Y1 - 2017/12/1

N2 - The revised International Staging System (R-ISS) has recently been developed to improve the risk stratification of multiple myeloma (MM) patients over the ISS. We assessed the R-ISS in MM patients who were treated with novel agents as a primary therapy and evaluated its discriminative power and ability to reclassify patients from the ISS. A total of 514 newly diagnosed MM patients treated with novel agents including thalidomide, bortezomib, and lenalidomide as a primary therapy were included in this retrospective analysis. With a median follow-up duration of 42.3 months (range, 40.5–44.1), the median overall survival (OS) was 61.0 months. There was a significant difference in median OS (not reached, 60.9, and 50.1 months for stages 1, 2, and 3, respectively, P < 0.001) among the three stages of R-ISS. The C-statistic was significantly greater for R-ISS than for ISS (0.769 vs. 0.696, P < 0.001). The event NRI was −0.08 (95% confidence interval [CI], −0.18–0.01) and the non-event NRI was 0.05 (95% CI, −0.03–0.10), resulting in a total NRI of −0.03 (95% CI, −0.14–0.08, P = 0.602). The R-ISS performs well and has significantly better discriminative power than the ISS in MM patients treated with novel agents as a primary therapy. However, it does not better reclassify patients from the ISS, suggesting that there is still room to improve the staging system. Moreover, new statistical measures for assessing and quantifying the risk prediction of new prognostic models are necessary in future studies.

AB - The revised International Staging System (R-ISS) has recently been developed to improve the risk stratification of multiple myeloma (MM) patients over the ISS. We assessed the R-ISS in MM patients who were treated with novel agents as a primary therapy and evaluated its discriminative power and ability to reclassify patients from the ISS. A total of 514 newly diagnosed MM patients treated with novel agents including thalidomide, bortezomib, and lenalidomide as a primary therapy were included in this retrospective analysis. With a median follow-up duration of 42.3 months (range, 40.5–44.1), the median overall survival (OS) was 61.0 months. There was a significant difference in median OS (not reached, 60.9, and 50.1 months for stages 1, 2, and 3, respectively, P < 0.001) among the three stages of R-ISS. The C-statistic was significantly greater for R-ISS than for ISS (0.769 vs. 0.696, P < 0.001). The event NRI was −0.08 (95% confidence interval [CI], −0.18–0.01) and the non-event NRI was 0.05 (95% CI, −0.03–0.10), resulting in a total NRI of −0.03 (95% CI, −0.14–0.08, P = 0.602). The R-ISS performs well and has significantly better discriminative power than the ISS in MM patients treated with novel agents as a primary therapy. However, it does not better reclassify patients from the ISS, suggesting that there is still room to improve the staging system. Moreover, new statistical measures for assessing and quantifying the risk prediction of new prognostic models are necessary in future studies.

UR - http://www.scopus.com/inward/record.url?scp=85029229686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029229686&partnerID=8YFLogxK

U2 - 10.1002/ajh.24891

DO - 10.1002/ajh.24891

M3 - Article

C2 - 28833417

AN - SCOPUS:85029229686

VL - 92

SP - 1280

EP - 1286

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 12

ER -